|
2024 Conference Publication Routine, prospective DPYD genotyping guided dose-individualisation for patients receiving fluoropyrimidines: Implementation, prevalence and patient safety outcomes from a multi-institutional clinical trialNalder, Mark, Kulasegaran, Tivya, Lundie, Ben, Woods, Rick, Eastgate, Melissa A., Wyld, David and Burge, Matthew E. (2024). Routine, prospective DPYD genotyping guided dose-individualisation for patients receiving fluoropyrimidines: Implementation, prevalence and patient safety outcomes from a multi-institutional clinical trial. 2024 ASCO Annual Meeting, Chicago, IL, United States, 31 May–4 June 2024. Alexandria, VA, United States: American Society of Clinical Oncology. doi: 10.1200/JCO.2024.42.16_suppl.12121 |
|
2024 Conference Publication Identifying optimized assessment of nerve damage during chemotherapyLi, Tiffany, Timmins, Hannah C, Mahfouz, Fawaz Mayez, Mizrahi, David, Horvath, Lisa, Harrison, Michelle L., Grimison, Peter S., Friedlander, Michael, Marx, Gavin M., Boyle, Frances M., Wyld, David, Henderson, Robert, King, Tracy, Baron-Hay, Sally E., Kiernan, Matthew C, Rutherford, Claudia, Goldstein, David and Park, Susanna B (2024). Identifying optimized assessment of nerve damage during chemotherapy. 2024 ASCO Annual Meeting, Chicago, IL United States, 31 May - 4 June 2024. Alexandria, VA United States: American Society of Clinical Oncology. doi: 10.1200/jco.2024.42.16_suppl.12016 |
|
2024 Conference Publication P3BEP (ANZUP 1302): An international randomized phase 3 trial of accelerated versus standard BEP chemotherapy for individuals aged 11-45 years with intermediate and poor-risk metastatic germ cell tumours (GCTs)Mak, Blossom, Tran, Ben, Pashankar, Farzana D., Mazhar, Danish, Huddart, Robert A., Wheater, Matthew, Walpole, Euan Thomas, Feldman, Darren R., Dunwoodie, Elaine, Lawrence, Nicola Jane, Birtle, Alison Jane, Wyld, David, Stevanovic, Amanda Gwendolyn, Balagtas, Jay Michael S., Stockler, Martin R., Davis, Ian D. and Australian and New Zealand Urogenital and Prostate Cancer Trials Group (ANZUP) (2024). P3BEP (ANZUP 1302): An international randomized phase 3 trial of accelerated versus standard BEP chemotherapy for individuals aged 11-45 years with intermediate and poor-risk metastatic germ cell tumours (GCTs). 2024 ASCO Genitourinary Cancers Symposium, San Francisco, CA United States, 25-27 January 2024. Alexandria, VA United States: American Society of Clinical Oncology. doi: 10.1200/jco.2024.42.4_suppl.tps524 |
|
2023 Conference Publication Factors that influence clinical trial participation for oncology patients in Australia: A scoping reviewYou, Kyung Ha, Lwin, Zarnie, Ahern, Elizabeth Stephanie, Roberts, Natasha Anne and Wyld, David (2023). Factors that influence clinical trial participation for oncology patients in Australia: A scoping review. 2023 ASCO Quality Care Symposium, Boston, MA United States, 27-28 October 2023. Alexandria, VA United States: American Society of Clinical Oncology. doi: 10.1200/op.2023.19.11_suppl.111 |
|
2023 Conference Publication P3BEP (ANZUP 1302): An international randomized phase 3 trial of accelerated versus standard BEP chemotherapy for male and female adults and children with intermediate and poor-risk metastatic germ cell tumours (GCTs)Zebic, Danka Sinikovic, Ben Tran,, Martin, Andrew James, Pashankar, Farzana D., Mazhar, Danish, Huddart, Robert A., Wheater, Matthew, Walpole, Euan Thomas, Dunwoodie, Elaine, Feldman, Darren R., Birtle, Alison Jane, Wyld, David, Lawrence, Nicola Jane, Stockler, Martin R. and Grimison, Peter S. (2023). P3BEP (ANZUP 1302): An international randomized phase 3 trial of accelerated versus standard BEP chemotherapy for male and female adults and children with intermediate and poor-risk metastatic germ cell tumours (GCTs). Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Chicago, IL USA, 2-6 June 2023. Philadelphia, PA USA: Lippincott Williams & Wilkins. |
|
2023 Conference Publication An international randomized phase 3 trial of accelerated versus standard BEP chemotherapy for male and female adults and children with intermediate and poor-risk metastatic germ cell tumours (GCTs)Zebic, Danka Sinikovic, Tran, Ben, Martin, Andrew James, Pashankar, Farzana D., Mazhar, Danish, Huddart, Robert A., Wheater, Matthew, Walpole, Euan Thomas, Dunwoodie, Elaine, Feldman, Darren R., Birtle, Alison Jane, Wyld, David, Lawrence, Nicola Jane, Stockler, Martin R., Grimison, Peter S. and Australian and New Zealand Urogenital and Prostate Cancer Trials Group (ANZUP) (2023). An international randomized phase 3 trial of accelerated versus standard BEP chemotherapy for male and female adults and children with intermediate and poor-risk metastatic germ cell tumours (GCTs). 2023 ASCO Annual Meeting, Chicago, IL USA, 2-6 June 2023. Alexandria, VA USA: American Society of Clinical Oncology. doi: 10.1200/jco.2023.41.16_suppl.tps5102 |
|
2023 Conference Publication PRRT for control of hypoglycaemia and disease progression due to metastatic insulinomaPattison, D. A., Kong, G., Hofman, M. S., Akhurst, T., Ravi, Kumar A. S., Michael, M., Wyld, D., Burge, M., Chiang, C., Sachithanandan, N., Love, A. and Hicks, R. (2023). PRRT for control of hypoglycaemia and disease progression due to metastatic insulinoma. 20th Annual ENETs Conference for the Diagnosis and Treatment of Neuroendocrine Tumor Disease, Electr Network, Mar 22-24, 2023. HOBOKEN: WILEY. |
|
2023 Conference Publication P3BEP (ANZUP 1302): An international randomized phase 3 trial of accelerated versus standard BEP chemotherapy for male and female adults and children with intermediate- and poor-risk metastatic germ cell tumours (GCTs)Zebic, Danka, Stockler, Martin R., Martin, Andrew James, Pashankar, Farzana D., Tran, Ben, Mazhar, Danish, Huddart, Robert A., Wheater, Matthew, Walpole, Euan Thomas, Dunwoodie, Elaine, Feldman, Darren R., Birtle, Alison Jane, Stevanovic, Amanda Gwendolyn, Wyld, David, Hanning, Fritha J., Grimison, Peter S. and Australian and New Zealand Urogenital and Prostate Cancer Trials Group (ANZUP) (2023). P3BEP (ANZUP 1302): An international randomized phase 3 trial of accelerated versus standard BEP chemotherapy for male and female adults and children with intermediate- and poor-risk metastatic germ cell tumours (GCTs). 2023 ASCO Genitourinary Cancers Symposium, San Francisco, CA United States, 16-18 February 2023. Alexandria, VA United States: American Society of Clinical Oncology. doi: 10.1200/jco.2023.41.6_suppl.tps431 |
|
2023 Conference Publication P3BEP (ANZUP 1302): an international randomized phase 3 trial of accelerated versus standard BEP chemotherapy for male and female adults and children with intermediateand poor-risk metastatic germ cell tumours (GCTs)Zebic, Danka, Stockler, Martin R., Martin, Andrew James, Pashankar, Farzana D., Ben Tran,, Mazhar, Danish, Huddart, Robert A., Wheater, Matthew, Walpole, Euan Thomas, Dunwoodie, Elaine, Feldman, Darren R., Birtle, Alison Jane, Stevanovic, Amanda Gwendolyn, Wyld, David, Hanning, Fritha J. and Grimison, Peter S. (2023). P3BEP (ANZUP 1302): an international randomized phase 3 trial of accelerated versus standard BEP chemotherapy for male and female adults and children with intermediateand poor-risk metastatic germ cell tumours (GCTs). Genitourinary Cancers Symposium, Virtual, 16-18 February 2023. Philadelphia, PA USA: Lippincott Williams & Wilkins. |
|
2022 Conference Publication Factors that influence cancer clinical trials participation in Australia: A scoping reviewYou, Kyung Ha (Kathy), Lwin, Zarnie, Ahern, Elizabeth, Wyld, David and Roberts, Natasha (2022). Factors that influence cancer clinical trials participation in Australia: A scoping review. HOBOKEN: WILEY. |
|
2022 Conference Publication Essential elements of optimal dietary and exercise referral practices for cancer survivors: Expert consensus for medical and nursing health professionalsJoseph, Ria, Hart, Nicolas H., Bradford, Natalie, Wallen, Matthew P., Han, Chad Y., Pinkham, Elizabeth P., Hanley, Brigid, Lock, Gemma, Wyld, David, Wishart, Laurelie, Koczwara, Bogda, Chan, Alexandre, Agbejule, Oluwaseyifunmi Andi, Crichton, Megan, Teleni, Laisa, Holland, Justin J., Edmiston, Kelli, Naumann, Leonie, Brown, Teresa and Chan, Raymond J. (2022). Essential elements of optimal dietary and exercise referral practices for cancer survivors: Expert consensus for medical and nursing health professionals. HOBOKEN: WILEY. |
|
2022 Conference Publication Cost-benefit of pre-treatment dihydropyrimidine dehydrogenase genotyping to individualise fluoropyrimidine-based chemotherapy in a contemporary Australian settingKim, Hansoo, Kulasegaran, Tivya, Eastgate, Melissa, Wyld, David, Burge, Matthew and Nalder, Mark (2022). Cost-benefit of pre-treatment dihydropyrimidine dehydrogenase genotyping to individualise fluoropyrimidine-based chemotherapy in a contemporary Australian setting. HOBOKEN: WILEY. |
|
2022 Conference Publication P3BEP (ANZUP 1302): An international randomised phase 3 trial of accelerated versus standard BEP chemotherapy for male and female adults and children with intermediate and poor-risk metastatic germ cell tumours (GCTs)Zebic, Danka, Stockler, Martin R., Martin, Andrew, Pashankar, Farzana, Ben Tran,, Mazhar, Danish, Huddart, Robert, Wheater, Matthew, Walpole, Euan, Dunwoodie, Elaine, Feldman, Darren, Birtle, Alison, Stevanovic, Amanda G., Wyld, David, Hanning, Fritha J. and Grimison, Peter S. (2022). P3BEP (ANZUP 1302): An international randomised phase 3 trial of accelerated versus standard BEP chemotherapy for male and female adults and children with intermediate and poor-risk metastatic germ cell tumours (GCTs). Clinical Oncology Society of Australia (COSA) 49th Annual Scientific Meeting, Brisbane, QLD, Australia, 2-4 November 2022. Chichester, West Sussex, United Kingdom: Wiley-Blackwell Publishing. doi: 10.1111/ajco.13869 |
|
2022 Conference Publication Appendiceal neuroendocrine tumours in individuals under the age of 50 years: A population-based study from Queensland, AustraliaMoorhead, William, Youl, Philippa, Moore, Julie and Wyld, David (2022). Appendiceal neuroendocrine tumours in individuals under the age of 50 years: A population-based study from Queensland, Australia. HOBOKEN: WILEY. |
|
2022 Conference Publication Salvage 177Lu-dotatate therapy in patients with progressive metastatic neuroendocrine tumorsHoe, Hui Jing and Wyld, David (2022). Salvage 177Lu-dotatate therapy in patients with progressive metastatic neuroendocrine tumors. Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Electr Network, Jun 03-07, 2022. PHILADELPHIA: LIPPINCOTT WILLIAMS & WILKINS. |
|
2022 Conference Publication Australasian Gastrointestinal Trials Group (AGITG) CONTROL NET Study: <SUP>177</SUP>Lu-DOTATATE peptide receptor radionuclide therapy (PRRT) and capecitabine plus temozolomide (CAPTEM) for pancreas and midgut neuroendocrine tumours (pNETS, mNETS)-Final resultsPavlakis, Nick, Ransom, David Turner, Wyld, David, Sjoquist, Katrin Marie, Wilson, Kate, Gebski, Val, Murray, James, Kiberu, Andrew Ddembe, Burge, Matthew E., Macdonald, William, Roach, Paul, Pattison, David A., Butler, Patrick, Price, Timothy Jay, Michael, Michael, Lawrence, Benjamin James, Bailey, Dale L., Leyden, Simone, Zalcberg, John Raymond and Turner, Harvey (2022). Australasian Gastrointestinal Trials Group (AGITG) CONTROL NET Study: 177Lu-DOTATATE peptide receptor radionuclide therapy (PRRT) and capecitabine plus temozolomide (CAPTEM) for pancreas and midgut neuroendocrine tumours (pNETS, mNETS)-Final results. Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Electr Network, Jun 03-07, 2022. PHILADELPHIA: LIPPINCOTT WILLIAMS & WILKINS. |
|
2021 Conference Publication 177Lu-DOTATATE peptide receptor radionuclide therapy (PRRT) in patients with somatostatin-expressing neuroendocrine tumors: a real-world retrospective review of efficacy and safety from an Australian tertiary cancer CenterNalder, Mark, Ladwa, Rahul, Raina, Anant, Burge, Matthew E., Love, Amanda, Pattison, David A., Ramsay, Stuart and Wyld, David (2021). 177Lu-DOTATATE peptide receptor radionuclide therapy (PRRT) in patients with somatostatin-expressing neuroendocrine tumors: a real-world retrospective review of efficacy and safety from an Australian tertiary cancer Center. 2021 ASCO Annual Meeting I, Virtual, 4-8 June 2021. Alexandria, VA USA: American Society of Clinical Oncology. doi: 10.1200/jco.2021.39.15_suppl.e16198 |
|
2020 Conference Publication P3BEP (ANZUP 1302): an international randomized phase III trial of accelerated versus standard BEP chemotherapy for adult and pediatric male and female patients with intermediate and poor-risk metastatic germ cell tumors (GCTs)Subramaniam, Shalini, Toner, Guy C., Stockler, Martin R., Martin, Andrew James, Pashankar, Farzana D., Frazier, A. Lindsay, Mazhar, Danish, Ford, Kate, Walpole, Euan Thomas, Stevanovic, Amanda Gwendolyn, Wyld, David, Troon, Simon, Hanning, Fritha J., Birtle, Alison Jane, Wheater, Matthew James, Huddart, Robert A., White, Jeff D., Spunt, Sheri L. and Grimison, Peter S. (2020). P3BEP (ANZUP 1302): an international randomized phase III trial of accelerated versus standard BEP chemotherapy for adult and pediatric male and female patients with intermediate and poor-risk metastatic germ cell tumors (GCTs). Genitourinary Cancers Symposium of the American-Society-of-Clinical-Oncology (ASCO), San Francisco, CA USA, 13-15 February 2020. Alexandria, VA: American Society of Clinical Oncology. |
|
2020 Conference Publication Insights into the practice patterns, challenges and the role of a shared care model in the management of neuroendocrine (NET) patients in the communityRadhika, Y., Chan, D., Thawer, A., Lo, D., Singh, S. and Wyld, D. (2020). Insights into the practice patterns, challenges and the role of a shared care model in the management of neuroendocrine (NET) patients in the community. 17th Annual ENETS Conference for the Diagnosis and Treatment of Neuroendocrine Tumor Disease, Electr Network, 11-13 March 2020. Basel, Switzerland: S. Karger. |
|
2019 Conference Publication Ontario oncologists' perspectives on addressing potential barriers in the management of patients with neuroendocrine tumorsFingrut, Warren, Yelamanchili, Radhika, Thawer, Alia, Chan, David, Wyld, David, Singh, Simron and Lo, Dorothy (2019). Ontario oncologists' perspectives on addressing potential barriers in the management of patients with neuroendocrine tumors. 11th Annual Meeting of the North American Neuroendocrine Tumor Society, Seattle, Washington, October 4-6, 2018. Philadelphia, PA, United States: Lippincott Williams & Wilkins. doi: 10.1097/MPA.0000000000001250 |
